Preheating of Femur Component in Hybrid Total Hip Arthroplasty
Comparison Between Preheated and Non-preheated Femur Component in Hybrid Total Hip Arthroplasty (THA) A Prospective Randomized Study of the 80 THA Using Radiostereometry.
1 other identifier
interventional
80
1 country
1
Brief Summary
Background
- Recently published studies confirm that preheating of femoral component enhances shear strength of implant-cement interface. Both Iesaka et al 2003 and Jafri et al 2004 showed reduction in cement porosity on cement-implant interface with preheated femur components. We will use the radiostereometry analysis (RSA) to investigate how the preheating of femur component influence on prosthesis survivorship. There are no clinical controlled studies performed to the date. The aim of the study
- Comparison of the migration rates between preheated and non-preheated femur components, analyzed with RSA. Methods
- Randomization of 80 patients into 2 groups with 40 in each. All patients will undergo standard hybrid total hip replacement. In group one the femur component (Bi-Metric, Interlock Biomet) will be preheated to 40 degrees of Celsius before cementation. In group two: the control group, the femur component will be of room temperature. We will measure the temperature at cement bone interface during the operation with use of thermocouple electrodes inserted through separate drill hole in the femur. The measurements will be recorded every 10 seconds. The patients will follow the standard postoperative rehabilitation program.
- The RSA analysis will be performed the first day after the operation and at 3, 12, 24 months postoperatively.
- The Dual-energy X-ray absorptiometry scanning (DEXA) of the femur will be performed at the first week after the operation and at 12 and 24 months postoperatively.
- The patients will be followed both clinically and radiologically at 1 and 2 years after the operation (Harris Hip Score).
- The results will be expressed as mean + SD (in mm). ANOVA statistical analysis will be used to confirm the differences between the groups.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2
Started May 2006
Typical duration for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 27, 2006
CompletedFirst Posted
Study publicly available on registry
April 27, 2006
CompletedStudy Start
First participant enrolled
May 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2010
CompletedApril 10, 2015
April 1, 2015
3.9 years
April 27, 2006
April 9, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Stem migration in mm
2 years
Secondary Outcomes (3)
Bone mineral density g/cm2
2 years
Temperature at bone-cement interface, degrees in Celsius
peroperatively
Serum- Titanium measurements in blood samples
Not defined
Interventions
Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
Eligibility Criteria
You may qualify if:
- The patients suffering of hip osteoarthritis
You may not qualify if:
- The patients with ASA score \>II
- The patients with cancer
- The secondary coxarthrosis after the trauma
- Any vascular or neuromuscular diseases affecting the hip.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Farsoe Hospital, Northern Orthopaedic Division
Farsø, 9640, Denmark
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mogens B Jørgensen, M.D.
Northern Orthopaedic Division, Aalborg University Hospital, Denmark
- PRINCIPAL INVESTIGATOR
Mogens B Laursen, M.D., Ph.D
Northern Orthopaedic Division, Aalborg University Hospital, Denmark
- PRINCIPAL INVESTIGATOR
Lotte Borgwardt, dr.
Frederikberg Hospital, Copenhagen
- STUDY CHAIR
Kjeld Søballe, Ph.D., MD.
University Hospital of Aarhus
- STUDY DIRECTOR
Poul T Nielsen, M.D.
Northern Orthopaedic Division, Aalborg University Hospital, Denmark
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 27, 2006
First Posted
April 27, 2006
Study Start
May 1, 2006
Primary Completion
April 1, 2010
Study Completion
April 1, 2010
Last Updated
April 10, 2015
Record last verified: 2015-04